Andreessen Horowitz has invested in AI companies disrupting the status quo across industries. We break down its top priorities across enterprise tech, healthcare, and beyond.
Artificial intelligence has driven profound cross-industry transformation in recent years — and interest in its potential has only accelerated amid the rise of generative AI.
Through its investment activity, VC powerhouse Andreessen Horowitz (a16z) is leaning into and propelling the shift.
Since the beginning of 2022, a16z has invested in a number of AI-focused companies to boost the efficiency and efficacy of key processes across industries, from enterprise data annotation to drug research and development.
Using CB Insights data, we mapped how Andreessen Horowitz has spread its AI investments across enterprise tech, healthcare, and beyond.
